- Home
- ARTL vs MTNB Comparison
ARTL vs MTNB Comparison
Compare ARTL & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARTL | MTNB |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ARTL | MTNB |
|---|---|---|
| Price | $5.86 | $0.50 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 16.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $0.48 |
| 52 Week High | $28.60 | $3.09 |
Technical Indicators
Market Signals| Indicator | ARTL | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 39.12 |
| Support Level | $2.24 | N/A |
| Resistance Level | $6.16 | $0.65 |
| Average True Range (ATR) | 2.41 | 0.06 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 17.37 | 14.21 |
Price Performance
Historical ComparisonAbout ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.